Skip to content

Clinical trial of shock wave prevent the occurrence of steroid type osteonecrosis of femoral head

Clinical trial of shock wave prevent the occurrence of steroid type osteonecrosis of femoral head

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-15007631
Enrollment
Unknown
Registered
2015-12-02
Start date
2016-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteonecrosis of femoral head

Interventions

ESWT:Shock Wave
Control group:No

Sponsors

China Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The ages between 18-65 years old, sex is not limited; 2. To be expected to use a large dose of corticosteroids, the amount of the use of steroid in accordance with the following three: (1) cumulative prednisone dosage greater than 2000mg; (2) prednisone more than 30mg/ days, for a month or more; (3) the use of high dose glucocorticoid therapy (methylprednisolone over 160mg/ days, methylprednisolone for 3 days and above). 3. Be able to understand this research and sign the consent for this trial.

Exclusion criteria

Exclusion criteria: 1. the primary disease is serious , not suitable for the study; 2. in the former has been diagnosed with femoral head necrosis; 3. pregnant or lactating women; 4. allergic constitution and allergic to a variety of drugs; 5. patients with severe heart disease, cerebrovascular disease, liver and renal insufficiency (liver function tests ALT or AST exceed 2 times the upper limit of normal values, renal function test creatinine or urea nitrogen exceed the upper limit of normal values), hematopoietic system diseases, severe digestive tract diseases, mental and central nervous system diseases; 6. bleeding tendency; 7. is not suitable for magnetic resonance examination (lesiure disease, with cardiac pacemakers, metal ring etc.); 8. the researchers considered not suitable for the study.

Design outcomes

Primary

MeasureTime frame
occurence of osteonecrosis;

Secondary

MeasureTime frame
Volume of lesion;

Countries

China

Contacts

Public ContactWei Sun
sun887@163.com+86 10 84206074

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026